EUVIMEDEUVIMED entdecken
Crossref

An evaluation of linezolid-associated serotonin toxicity in combination with serotonergic agents at a community teaching hospital

Christopher Donaldson, John Cerenzio, Justin Andrade

American Journal of Health-System Pharmacy · 2026

DOI: 10.1093/ajhp/zxaf358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, 2026. Verfasst von Christopher Donaldson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical University of South Carolina Health - Orangeburg, Orangeburg, SC, USA. Hauptthemen laut MEDLINE: Linezolid, Hospitals, Teaching, Serotonin Syndrome, Serotonin Agents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The purpose of this study was to assess demographic and clinical characteristics and potential risk factors for linezolid-associated serotonin toxicity in patients receiving linezolid and concomitant serotonergic agents.

Methods

This was a single-center, retrospective, single-cohort study. Adults at least 18 years of age who were ordered linezolid from January 1, 2014, through October 31, 2023, were screened for inclusion. Patients were included if they received at least one dose of linezolid and a concomitant serotonergic agent. Patients were excluded if the medications were administered more than 24 hours apart or if the patient was pregnant or lactating. All concomitant serotonergic agents were assessed and assigned a dose category based on typical dosing ranges for FDA-approved indications. Serotonin toxicity was assessed utilizing data from the electronic medical record and was defined according to the Sternbach or Hunter criteria.

Results

Of the 615 patients screened, 227 adults met the inclusion criteria with administration of linezolid and a concomitant serotonergic agent. The mean age was 62.4 years, and the mean duration of linezolid treatment was 5.5 days. Most patients were administered only one concomitant medication (59.9%), and most were classified as receiving a low dose (69.1%). Only 2 patients (0.0%) were identified with possible serotonin toxicity as defined by the Sternbach or Hunter criteria, with one case possibly associated with linezolid.

Conclusion

The incidence of serotonin toxicity in hospitalized patients receiving linezolid with concomitant serotonergic agents was low in our study. Linezolid is likely safe in patients receiving select concomitant agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidHospitals, TeachingSerotonin SyndromeSerotonin AgentsAnti-Bacterial AgentsHumansRetrospective StudiesFemaleMiddle AgedMaleAgedHospitals, CommunityRisk FactorsAdultDrug InteractionsCohort StudiesDrug Therapy, CombinationAged, 80 and over

Stichwörter der Autor:innen

linezolidserotoninserotonin syndromeserotonin toxicity

Substanzen

LinezolidSerotonin AgentsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Medical University of South Carolina Health - Orangeburg, Orangeburg, SC, USA.
  • The Brooklyn Hospital Center, Brooklyn, NY, USA.
  • Touro College of Pharmacy, New York, NY, and The Brooklyn Hospital Center, Brooklyn, NY, USA.

Zitieren

APA

Donaldson, C., Cerenzio, J., & Andrade, J. (2026). An evaluation of linezolid-associated serotonin toxicity in combination with serotonergic agents at a community teaching hospital. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaf358

Vancouver

Donaldson C, Cerenzio J, Andrade J. An evaluation of linezolid-associated serotonin toxicity in combination with serotonergic agents at a community teaching hospital. American Journal of Health-System Pharmacy. 2026. doi:10.1093/ajhp/zxaf358

BibTeX
@article{Donaldson2026,
  author = {Donaldson, Christopher and Cerenzio, John and Andrade, Justin},
  title = {An evaluation of linezolid-associated serotonin toxicity in combination with serotonergic agents at a community teaching hospital},
  journal = {American Journal of Health-System Pharmacy},
  year = {2026},
  doi = {10.1093/ajhp/zxaf358}
}
Kostenlos starten →